Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.88
(
-0.83%
)
Bitcoin
81,039.84
(
0.68%
)
News Focus
News Focus
Post# of 257553
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 227705

Saturday, 12/14/2019 2:47:26 PM

Saturday, December 14, 2019 2:47:26 PM

Post# of 257553
Re: Vascepa vs Inclisiran NPV

Well, I wouldn’t have posed the question if I thought the answer were obvious, so it follows that I respectfully disagree with your conclusion.

I suspect that you are applying a substantially larger CVOT-failure discount to Inclisiran than I am.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today